Form 4: Fennec Pharmaceuticals CEO Granted 400,000 Stock Options
SEC Form 4 Filing
Fennec Pharmaceuticals' CEO, Jeffrey S. Hackman, was granted incentive stock options to purchase 400,000 shares of the company's common stock on August 15, 2024.
Summary
- Jeffrey S. Hackman, the CEO of Fennec Pharmaceuticals, was granted incentive stock options on August 15, 2024.
- The options are for 400,000 shares of Fennec Pharmaceuticals' common stock.
- The exercise price of the options is $5.58 per share.
- The options were granted pursuant to the Issuer's 2020 Equity Incentive Plan.
- The options vest in installments, starting August 5, 2025, and are fully vested by August 5, 2027.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and aligns management's interests with shareholders. The vesting schedule promotes long-term value creation.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance.
Risks
- The exercise of these options could dilute existing shareholders' equity.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Fennec's size and stage.
Comparison to Industry Standards
- Stock option grants to CEOs in the pharmaceutical industry are common, with vesting schedules typically ranging from three to five years.
- The number of shares granted is within the typical range for companies of Fennec Pharmaceuticals' size and market capitalization.
- Comparable companies such as Agenus and Celldex Therapeutics also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may experience dilution if the options are exercised.
- Employees may be motivated by the CEO's increased alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Date of stock options grant |
| 08/05/2025 | Vesting Commencement Date |
| 08/05/2027 | Date when 100% of the options are vested |
| 08/05/2034 | Expiration date of the options |
| 08/19/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.